Table 2.
Baseline Characteristics of the Cohort
| Cohort Characteristics | |
|---|---|
|
| |
| Sex, % (n) | |
| Male | 15.7% (94) |
| Female | 84.3% (504) |
|
| |
| Weight, kg (median ± SD*) | 80.7 ± 22.6 |
|
| |
| Height, in (median ± SD) | 65.0 ± 3.3 |
|
| |
| Age, years (median ± SD) | 51.1 ± 14.1 |
|
| |
| BMI†, kg/m2 (median ± SD) | 29.3 ± 8.1 |
|
| |
| Smoker, % (n) | |
| Yes | 18.7% (112) |
| No | 81.3% (486) |
|
| |
| Pre-operative TSH‡ (median ± SD) | 0.8 ± 2.4 |
|
| |
| Indication for Surgery, % (n) | |
| -Thyroid Nodular Disease/Multinodular Goiter | 57.5% (344) |
| -Hyperthyroidism | 42.5% (254) |
| -Graves’ Hyperthyroidism | 66.5% (169) |
|
| |
| Hashimoto’s Disease | 18.4% (110) |
|
| |
| Iron Supplementation, % (n) | |
| Yes | 2.5% (15) |
| No | 97.5% (583) |
|
| |
| Multivitamin-mineral use, % (n) | |
| Yes | 13.2% (79) |
| No | 86.8% (519) |
|
| |
| Weeks to Euthyroidism (median ± SD) | 16.5 ± 17.9 |
|
| |
| Initial LT4§ Dose, μg/day (median ± SD) | 125 ± 29.2 |
|
| |
| Euthyroid LT4 Dose, μg/day (median ± SD) | 125 ± 38.9 |
|
| |
| Pre-operative LT4 use, % (n) | |
| Yes | 17.2% (103) |
| No | 82.8% (495) |
*
SD = standard deviation;
†
BMI = body mass index;
‡
TSH = thyroid-stimulating hormone;
§
LT4 = levothyroxine